High Cell-Free DNA Integrity Is Associated with Poor Breast Cancer Survival

被引:11
作者
Lamminaho, Maria [1 ]
Kujala, Jouni [1 ]
Peltonen, Hanna [1 ]
Tengstrom, Maria [2 ]
Kosma, Veli-Matti [1 ,3 ,4 ,5 ]
Mannermaa, Arto [1 ,4 ,5 ]
机构
[1] Univ Eastern Finland, Inst Clin Med Pathol & Forens Med, FI-70211 Kuopio, Finland
[2] Kuopio Univ Hosp, Canc Ctr, FI-70029 Kuopio, Finland
[3] Kuopio Univ Hosp, Dept Clin Pathol, FI-70029 Kuopio, Finland
[4] Univ Eastern Finland, Multidisciplinary Canc Res Community RC Canc, FI-70211 Kuopio, Finland
[5] Kuopio Univ Hosp, Biobank Eastern Finland, FI-70029 Kuopio, Finland
关键词
liquid biopsy; biomarker; DNA fragmentation; diagnostics; PLASMA; MARKER; SIZE;
D O I
10.3390/cancers13184679
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary A recent point of focus in breast cancer (BC) research has been the utilization of cell-free DNA and its concentration (cfDConc) and integrity (cfDI) as potential biomarkers. Though the association of cfDConc and BC survival is already recognized, studies on the prognostic value of cfDI have had contradictory results. The aim of this study was to investigate the prognostic potential of cfDConc and cfDI in Eastern Finnish BC cases with a non-metastatic disease. While the prognostic value of cfDConc remained non-significant in our analyses, high cfDI was an independent prognostic factor for poor overall survival (OS) and breast cancer-specific survival (BCSS). Inclusion of cfDI in the multivariate logistic regression model improved the predictive performance of the model, thus suggesting that the combined use of traditional tumor features and liquid biopsy could help to discriminate BC patients with poor OS and BCSS more accurately at the time of diagnosis. Background: A recent point of focus in breast cancer (BC) research has been the utilization of cell-free DNA (cfDNA) and its concentration (cfDConc) and integrity (cfDI) as potential biomarkers. Though the association of cfDConc and poor survival is already recognized, studies on the prognostic value of cfDI have had contradictory results. Here, we provide further evidence to support the use of cfDI as a potential biomarker. Methods: We selected 204 Eastern Finnish BC cases with non-metastatic disease and isolated cfDNA from the serum collected at the time of diagnosis before any treatment was given. The cfDConc and cfDI were measured with a fluorometer and electrophoresis and analyzed with 25 years of survival data. Results: High cfDConc was not an independent prognostic factor in our analyses while high cfDI was found to be an independent prognostic factor for poor OS (p = 0.020, hazard ratio (HR) = 1.57, 95% confidence interval (CI) 1.07-2.29, Cox) and BCSS (p = 0.006, HR = 1.93, 95% CI 1.21-3.08)). Inclusion of cfDI in the multivariate logistic regression model improved the predictive performance. Conclusions: Our results show high cfDI is an independent prognostic factor for poor OS and BCSS and improves the predictive performance of logistic regression models, thus supporting its prognostic potential.
引用
收藏
页数:11
相关论文
共 23 条
[1]   Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries [J].
Allemani, Claudia ;
Matsuda, Tomohiro ;
Di Carlo, Veronica ;
Harewood, Rhea ;
Matz, Melissa ;
Niksic, Maja ;
Bonaventure, Audrey ;
Valkov, Mikhail ;
Johnson, Christopher J. ;
Esteve, Jacques ;
Ogunbiyi, Olufemi J. ;
Azevedo e Silva, Gulnar ;
Chen, Wan-Qing ;
Eser, Sultan ;
Engholm, Gerda ;
Stiller, Charles A. ;
Monnereau, Alain ;
Woods, Ryan R. ;
Visser, Otto ;
Lim, Gek Hsiang ;
Aitken, Joanne ;
Weir, Hannah K. ;
Coleman, Michel P. .
LANCET, 2018, 391 (10125) :1023-1075
[2]   Effects of preanalytical factors on the molecular size of cell-free DNA in blood [J].
Chan, KCA ;
Yeung, SW ;
Lui, WB ;
Rainer, TH ;
Lo, YMD .
CLINICAL CHEMISTRY, 2005, 51 (04) :781-784
[3]   Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer [J].
Cheng, Jie ;
Holland-Letz, Tim ;
Wallwiener, Markus ;
Surowy, Harald ;
Cuk, Katarina ;
Schott, Sarah ;
Trumpp, Andreas ;
Pantel, Klaus ;
Sohn, Christof ;
Schneeweiss, Andreas ;
Burwinkel, Barbara .
BREAST CANCER RESEARCH AND TREATMENT, 2018, 169 (01) :69-82
[4]   Size distribution of circulating cell-free DNA in sera of breast cancer patients in the course of adjuvant chemotherapy [J].
Deligezer, Ugur ;
Eralp, Yesim ;
Akisik, Ebru E. ;
Akisik, Elif Z. ;
Saip, Pinar ;
Topuz, Erkan ;
Dalay, Nejat .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2008, 46 (03) :311-317
[5]   Cell-Free DNA as a Biomarker in Autoimmune Rheumatic Diseases [J].
Duvvuri, Bhargavi ;
Lood, Christian .
FRONTIERS IN IMMUNOLOGY, 2019, 10
[6]   Putative Origins of Cell-Free DNA in Humans: A Review of Active and Passive Nucleic Acid Release Mechanisms [J].
Grabuschnig, Stefan ;
Bronkhorst, Abel Jacobus ;
Holdenrieder, Stefan ;
Rodriguez, Ingund Rosales ;
Schliep, Klaus Peter ;
Schwendenwein, Daniel ;
Ungerer, Vida ;
Sensen, Christoph Wilhelm .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (21) :1-24
[7]   Circulating cell-free DNA and its integrity as a prognostic marker for breast cancer [J].
Iqbal, Sobuhi ;
Vishnubhatla, Sreenivas ;
Raina, Vinod ;
Sharma, Surabhi ;
Gogia, Ajay ;
Deo, Suryanarayana S. V. ;
Mathur, Sandeep ;
Shukla, Nutan Kumar .
SPRINGERPLUS, 2015, 4
[8]  
Jahr S, 2001, CANCER RES, V61, P1659
[9]   Circulating cell-free DNA is associated with cardiometabolic risk factors: The Health 2000 Survey [J].
Jylhava, Juulia ;
Lehtimaki, Terho ;
Jula, Antti ;
Moilanen, Leena ;
Kesaniemi, Y. Antero ;
Nieminen, Markku S. ;
Kahonen, Mika ;
Hurme, Mikko .
ATHEROSCLEROSIS, 2014, 233 (01) :268-271
[10]   Plasma DNA integrity index as a potential molecular diagnostic marker for breast cancer [J].
Kamel, Azza M. ;
Teama, Salwa ;
Fawzy, Amal ;
El Deftar, Mervat .
TUMOR BIOLOGY, 2016, 37 (06) :7565-7572